Randall C Starling
Overview
Explore the profile of Randall C Starling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
453
Citations
11437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nouhravesh N, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e037899.
PMID: 39968788
Background: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in-hospital. Thus, this prespecified PARAGLIDE-HF (Prospective Comparison of ARNI With...
2.
Triposkiadis F, Briasoulis A, Starling R, Magouliotis D, Kourek C, Zakynthinos G, et al.
Curr Probl Cardiol
. 2025 Feb;
50(4):103019.
PMID: 39954876
Hereditary transthyretin (TTR) amyloidosis (ATTRv amyloidosis) is a devastating disease characterized by broad range of clinical manifestations, including predominantly neurological, predominantly cardiac, and mixed phenotypes. This wide phenotypic variability hindered...
3.
Abadie B, Elghoul Y, Prakash S, Besir B, Ziada K, Jacob M, et al.
Eur Heart J Cardiovasc Imaging
. 2025 Feb;
PMID: 39919052
Background: Cardiac allograft vasculopathy (CAV) affects both epicardial and microvascular coronary arteries, however few studies have characterized microvascular dysfunction in this population. Several prior studies have shown positron emission tomography/computed...
4.
Nouhravesh N, Gunn A, Cyr D, Hernandez A, Morrow D, Velazquez E, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792134
Aims: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction...
5.
Weiss A, Maigrot J, Tong M, Thuita L, Smedira N, Unai S, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39783781
Aims: As patients experience longer survival on HeartMate 3 left ventricular assist devices, there is a need to characterize long-term risks of adverse outcomes more precisely. This study characterized temporal...
6.
Maigrot J, Thuita L, Tong M, Soltesz E, Smedira N, Unai S, et al.
JTCVS Open
. 2024 Nov;
21:123-137.
PMID: 39534347
Objectives: To identify possible etiology-specific differences in preoperative risk factors for major adverse events during Impella 5.5 support in patients with ischemic (ICM) and nonischemic cardiomyopathy (NICM). Methods: From October...
7.
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, et al.
Am Heart J
. 2024 Nov;
280:70-78.
PMID: 39505123
Background: The win ratio (WR) is an emerging alternative for reporting composite outcomes, prioritizing clinically significant events such as mortality while incorporating surrogate measures. However, its benefits should be weighed...
8.
Maigrot J, Starling R, Soltesz E, Smedira N, Tong M, Unai S, et al.
Artif Organs
. 2024 Oct;
49(1):137-145.
PMID: 39422190
Background: Impella 5.5 is a temporary left ventricular assist device utilized to support patients with cardiogenic shock and those undergoing high-risk cardiac interventions. Methods: From October 2019 to January 2023,...
9.
Abushouk A, Layoun H, Harb S, Miyasaka R, Albert C, Starling R, et al.
J Card Fail
. 2024 Oct;
30(10):1265-1272.
PMID: 39389736
Novel transcatheter therapies for tricuspid regurgitation (TR) appear promising, yet their applicability to an all-comer TR population remains unclear. We aimed to assess the feasibility of emerging transcatheter tricuspid therapies...
10.
Longinow J, Martens P, Ilgiovine Z, Higgins A, Ives L, Soltesz E, et al.
J Card Fail
. 2024 Oct;
30(10):1255-1264.
PMID: 39389735
Background: In those with heart failure-related cardiogenic shock (HF-CS), an intra-aortic balloon pump (IABP) may improve hemodynamics and be useful as a bridge to advanced therapies. We explore whether those...